PA-BOOMI
6.8.2024 15:01:34 CEST | Business Wire | Press release
Boomi™, the intelligent integration and automation leader, today announced the release of a new report, “A Playbook for Crafting AI Strategy,” produced in collaboration with MIT Technology Review Insights. This comprehensive study — which includes a global survey of C-suite and senior data executives, including in-depth interviews conducted with business leaders on data and AI — sheds light on the current state of enterprise AI adoption, and offers actionable strategies for navigating the transformative landscape of artificial intelligence.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240806027370/en/
Boomi Releases Strategic Playbook for Effective AI Adoption (Graphic: Business Wire)
As businesses grapple with ambitious AI predictions — such as PwC's forecast that AI could contribute an astounding $15.7 trillion to global GDP by 20301 — major hurdles remain in the journey from pilot projects to enterprise-wide deployment. As an example, just 5.4% of US businesses utilized AI to produce a product or service in 2024,2 signifying a pressing need for strategic and organizational shifts to leverage AI effectively.
Key findings from the report highlight the following trends and challenges:
- AI ambitions are substantial, but few have scaled beyond pilots. Fully 95% of companies surveyed are already using AI and 99% expect to in the future. But few organizations have graduated beyond pilot projects: 76% have deployed AI in just one to three use cases. As half of companies expect to fully deploy AI across all business functions within two years, this year is key to establishing foundations for enterprise-wide AI.
- AI-readiness spending is slated to rise significantly. Overall, AI spending in 2022 and 2023 was modest or flat for most companies, with only one in four increasing their spending by more than a quarter. That is set to change in 2024, with nine in ten respondents expecting to increase AI spending on data readiness (including platform modernization, cloud migration, and data quality) and in adjacent areas like strategy, cultural change, and business models. Four in ten expect to increase spending by 10 to 24%, and one-third expect to increase spending by 25 to 49%.
- Data liquidity is one of the most important attributes for AI deployment. The ability to seamlessly access, combine, and analyze data from various sources enables firms to extract relevant information and apply it effectively to specific business scenarios. It also eliminates the need to sift through vast data repositories, as the data is already curated and tailored to the task at hand.
- Data quality is a major limitation for AI deployment. Half of respondents cite data quality as the most limiting data issue in deployment. This is especially true for larger firms with more data and substantial investments in legacy IT infrastructure. Companies with revenues of over $10 billion are the most likely to cite both data quality and data infrastructure as limiters, suggesting that organizations presiding over larger data repositories find the problem substantially harder.
- Companies are not rushing into AI. Nearly all organizations (98%) say they are willing to forgo being the first to use AI if that ensures they can deliver it safely and securely. Governance, security, and privacy are the biggest brake on the speed of AI deployment, cited by 45% of respondents (and a full 65% of respondents from the largest companies).
“Over the last year, organizations have come to understand the power and potential of AI,” said Matt McLarty, CTO at Boomi. “This year, those organizations are seeking to shift from small pilots to enterprise-wide deployment of AI at scale.”
“A Playbook for Crafting AI Strategy” can assist with the next steps of an AI journey, offering the following principles as guidance:
- This is a critical year for building AI foundations. As organizations strive to meet ambitious short-term AI goals, they are discovering that having the right data foundation is critical. Organizations are doubling down on investments in data quality, data liquidity, and IT infrastructure.
- The highest-leverage AI use cases drive targeted, business-specific results. Although general-purpose generative AI use cases are increasingly simple to implement, they are equally available to competitors and customers. The most valuable use cases are those that create unique competitive advantages for the business.
- Financial considerations and partnerships are key. This year, the costs of AI — from GPUs to skilled talent to energy consumption — must be accounted for, and a realistic approach to measuring AI’s ROI must be developed. Because few organizations will go it alone when it comes to AI, making decisions about the right partners, vendors, and tools will be essential to most companies’ AI futures.
- Speed of AI adoption is being moderated by a realistic assessment of its risks. Organizations are rightly cautious about the risks posed by injudicious use of AI, and essentially all agree that caution is preferable to first-mover advantage when scaling AI. An emerging regulatory environment and a better understanding of how the risks of AI can be mitigated should serve to speed adoption.
“The biggest factor holding back AI implementation is not knowing where to start,” said Matt McLarty, CTO at Boomi. “You don’t actually have to be an expert on how to create generative AI in order to get value from generative AI. As organizations seek to harness AI's transformative potential, our report serves as a crucial playbook, guiding business leaders through the complexities of AI strategy formulation.”
Download the complete report, “A Playbook for Crafting AI Strategy.”
Additional Resources
- Learn more about the Boomi Enterprise Platform
- Follow Boomi on X (Twitter), LinkedIn, Facebook, and YouTube
About Boomi
Boomi, the intelligent integration and automation leader, helps organizations around the world automate and streamline critical processes to achieve business outcomes faster. Harnessing advanced AI capabilities, the Boomi Enterprise Platform seamlessly connects systems and manages data flows with API management, integration, data management, and AI orchestration in one comprehensive solution. With a customer base exceeding 20,000 companies globally and a rapidly expanding network of 800+ partners, Boomi is revolutionizing the way enterprises of all sizes achieve business agility and operational excellence. Discover more at boomi.com.
© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
__________________________
1 Sizing the prize: What’s the real value of AI for your business and how can you capitalise?” PwC, 2017, https://preview.thenewsmarket.com/Previews/PWC/DocumentAssets/476830.pdf.
2 Richard Vanderford, “Generative AI Isn’t Ubiquitous in the Business World—at Least Not Yet,” The Wall Street Journal, April 7, 2024, https://www.wsj.com/articles/generative-ai-isnt-ubiquitous-in-the-business-worldat-least-not-yet-07c07f01?mod=tech_lead_pos3.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806027370/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RevolKa Reimagines Antibody Engineering with "RevoAb®"1.4.2026 06:30:00 CEST | Press release
A Same-day Sequence Optimization Service to Elevate Antibody Expression Levels by RevolKa’s advanced AI Protein Engineering Engine RevolKa Ltd. (RevolKa), a venture-backed biotech company providing an advanced AI protein engineering technology platform, called aiProtein®, is pleased to announce the official global launch of RevoAb®, an innovative and quick online service for antibody sequence optimization to solve challenges in physicochemical properties, especially antibodyyields. RevoAb®:The Next-Gen AI Antibody Design Since December 2023, RevolKa has provided an antibody optimization services utilizing aiProtein®. The newly launched RevoAb® is a quick intuitive online antibody sequence optimization service that integrates RevolKa’s core technology—the "Refined Naturalness Framework Engineering". RevoAb® is designed to generate antibody framework sequences optimized for improved physicochemical properties, especially protein expression levels, without trade-off of affinity. This allo
Global Beauty Market Grows 10% as AI and E-commerce Reshape Consumer Buying1.4.2026 03:00:00 CEST | Press release
Online sales outpace in-store by 6x as digital-first and AI-influenced commerce accelerates globally NielsenIQ (NYSE:NIQ), a global leader in consumer intelligence, today released its State of Beauty 2026 report, showing the global beauty market grew 10% year-on-year, with E-commerce expanding six times faster than in-store sales. The findings highlight a rapid shift to digital-first, AI-influenced commerce across key global markets. As consumer expectations evolve toward convenience, personalization, and seamless digital experiences, beauty brands are under increasing pressure to adapt. From AI-powered product discovery to social commerce and livestream shopping, the path to purchase is becoming more dynamic—requiring brands to move faster and engage consumers across an increasingly complex ecosystem. Key findings from the State of Beauty 2026 report: Global beauty sales grew 10% year-over-year, driven by strong digital acceleration E-commerce is growing 6x faster than in-store sales,
bet365 Partners with TestMu AI to Accelerate Global Release Velocity with Agentic AI Quality Engineering31.3.2026 19:01:00 CEST | Press release
Streamlines Hillside Technology testing across browsers and mobile devices while supporting rapid expansion into regulated markets. TestMu AI (Formerly LambdaTest), the world's first full-stack Agentic AI Quality Engineering platform, today announced that Hillside Technology Limited, the technology powerhouse behind global online gambling leader bet365, has adopted its platform to unify software testing and support hundreds of weekly production releases. The global online gaming industry is currently experiencing a massive shift, with the market projected to exceed $150 billion by 2030. As mobile gaming becomes the primary touchpoint for users, the technical complexity of delivering a seamless, low-latency experience has grown exponentially. For industry giants like bet365, the need to validate software across an infinite matrix of hardware, screen resolutions, and OS versions is a mission-critical requirement. This partnership ensures that, as gaming becomes more mobile-centric, bet36
IFF Secures First Heart Health Claim for Soy Protein in Australia and New Zealand31.3.2026 16:00:00 CEST | Press release
Regulatory milestone opens heart health growth opportunities for food and beverage manufacturers IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and health & biosciences announced today that a new heart health claim for isolated soy protein has been accepted by the Food Standards Australia New Zealand (FSANZ). The approval enables food and beverage manufacturers in Australia and New Zealand to link soy protein consumption with healthy blood cholesterol levels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330523416/en/ First heart health claim approved for soy protein in Australia and New Zealand. “For decades, IFF has invested in the science behind soy protein and its role in supporting cardiovascular health,” said Tony Andrew, vice president of protein solutions for IFF Food Ingredients. “This approved claim validates years of rigorous research and collaboration. With our deep expertise in ing
Sub-Q Bionics Closes $1.5M Pre-Seed Round to Advance Next-Generation Solution for Lymphedema Care31.3.2026 15:26:00 CEST | Press release
Sub-Q Bionics, a medical device company developing next-generation solutions to improve care for patients living with lymphedema, today announced the successful close of its $1.5 million pre-seed funding round. The round includes investment from Mayo Clinic and Yeda, the technology transfer company of the Weizmann Institute of Science, as well as several private investors. The Israel Innovation Authority also provided matching funds. The funding will enable Sub-Q Bionics to continue to develop its novel bionic lymph node technology designed to transform how lymphedema is managed, based on scientific innovations from the Weizmann Institute and Shamir Medical Center. The system aims to provide a solution to manage fluid with a subcutaneous implant that will allow patients freedom of movement, automatic fluid management and reduction of symptoms such as pain and swelling. Lymphedema affects millions of patients worldwide, especially breast cancer survivors, and remains significantly under
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
